Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Dibasic sodium phosphate + monobasic sodium phosphate** is a combination of inorganic phosphate salts used primarily as an osmotic laxative for bowel cleansing prior to colonoscopy, surgery, or rectal exams, and as a phosphate replacement therapy for hypophosphatemia via intravenous administration. It functions by increasing solute concentration in the intestinal lumen, drawing water into the colon to induce diarrhea and evacuation. Available in oral tablets, solutions, rectal enemas, and IV injections, it requires caution due to risks of electrolyte imbalances like hyperphosphatemia, hypocalcemia, hypokalemia, dehydration, acute kidney injury, and QT prolongation, particularly in patients with renal impairment, heart failure, or the elderly.[1][2][3][5][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dibasic sodium phosphate + monobasic sodium phosphate.